Afatinib (Gitarel) indication scope and evaluation of therapeutic effect

Afatinib (Afatinib) is an irreversible pan-ErbB family receptor tyrosine kinase inhibitor (TKI), mainly used to treat patients with non-small cell lung cancer (NSCLC) with specific EGFR gene mutations. It can inhibit EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) signal transduction, thus blocking the proliferation and survival signals of tumor cells. Afatinib is approved in many countries and is often used as a first-line treatment for EGFR mutation-positive advanced or metastatic non-small cell lung cancer, providing an important targeted treatment option for such patients.

In terms of indications, afatinib is mainly used to treat locally advanced or metastatic non-small cell lung cancer carrying sensitive EGFR mutations (such as Exon 19 deletions or Exon 21 L858R mutations). In addition, afatinib is also suitable for some patients with rare EGFR mutations, such as G719X, L861Q and S768I and other mutation types, which have a wider mutation coverage than other first-generation EGFR-TKI clinically. In addition, afatinib is also used to treat patients who have progressed after platinum-containing chemotherapy and carry HER2 mutations, providing more treatment options for patients with clear molecular classifications.

From an efficacy perspective, clinical studies have shown that afatinib improves progression-free survival (PFS< span>) is significantly better than traditional chemotherapy, with the average PFS reaching more than 11 months, and some patients can even reach more than two years. With the first generationEGFR-TKI(such as gefitinib, erlotinib), afatinib is more effective and has a higher disease control rate in patients with rare mutation types and brain metastases. In addition, some studies have also shown that afatinib as first-line treatment, combined with other subsequent treatment options, can help prolong overall survival (OS).

In general, afatinib has definite efficacy in the treatment of EGFR mutation-positiveNSCLC, especially for some patients with rare mutations and patients with brain metastases. It has better therapeutic advantages. Although adverse reactions such as diarrhea, rash, and stomatitis may occur during use, most of them can be controlled through dose adjustment and symptomatic treatment. Therefore, rational selection of indications and standardized medication are of great significance to maximize the efficacy of afatinib and improve patients' quality of life.

Reference materials:https://www.drugs.com/